First line therapy with DMT with moderate efficacy

Safety and efficacy of teriflunomide in paediatric MS (TERIKIDS)

• The IPMSSG guidelines recommend early initiation of DMTs with either an INTERFERON- β or GLATIRAMER ACETATE based on evidence from open-label multi-center studies

• TERIFLUNOMIDE approved by EMA indication in paediatric patients aged ≥ 10 years in 2021, but not recommended in some countries

Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 2012;18:116-127; Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon beta- 1b in pediatric multiple sclerosis. Neurology. 2006; Tenembaum SN, Banwell B, Pohl D, et al. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol. 2013

Second line DMT with high efficacy

• PARADIGMS study FINGOLIMOD was associated with a lower rate of relapse and less accumulation of lesions on MRI over a 2-year period than IFN beta-1a

• In 2018, the FDA and the EMA approved theindications of fingolimod in children with relapsing MS